

**FISCAL IMPACT OF PROPOSED LEGISLATION**

**Measure: HB 2617 - 3**

82nd Oregon Legislative Assembly – 2023 Regular Session

Legislative Fiscal Office

*Only Impacts on Original or Engrossed Versions are Considered Official*

Prepared by: MaryMichelle Sosne

Reviewed by: Steve Robbins

Date: 3/2/2023

**Measure Description:**

Directs Oregon Health Authority, in consultation with Newborn Bloodspot Screening Advisory Board, to adopt rules for board to evaluate and recommend adding disease to or removing disease from newborn bloodspot screening panel or taking no action on disease.

**Government Unit(s) Affected:**

Oregon Health Authority

**Summary of Fiscal Impact:**

Costs related to the measure may require budgetary action - See analysis.

**Summary of Expenditure Impact:**

	<b>2023-25 Biennium</b>	<b>2025-27 Biennium</b>
<b>Oregon Health Authority</b>		
<b>General Fund</b>		
Personal Services	\$166,977	\$222,638
Services and Supplies	\$313,155	\$317,026
<b>Total General Fund</b>	<b>\$480,132</b>	<b>\$539,664</b>
<b>Total Fiscal Impact</b>	<b>\$480,132</b>	<b>\$539,664</b>
<i>Total Positions</i>	1	1
<i>Total FTE</i>	0.75	1.00

**Analysis:**

HB 2617-3 updates membership, reporting and meeting requirements for the Newborn Bloodspot Screening Advisory Board (NBSAB); changes to membership are effective July 1, 2024. The measure directs the Oregon Health Authority (OHA), in consultation with NBSAB, to develop rules for determining the addition or removal of a disease to the newborn bloodspot screening panel. The measure, as amended, directs OHA to consider and if possible implement, the addition of a disease to the newborn bloodspot screening panel no later than 18 months after the Advisory Committee on Heritable Disorders in Newborns and Children submits a recommendation; this applies to recommendations made on or after January 1, 2022. OHA is directed to conduct a pilot study demonstrating the adopted rules, policies and criteria and submit a preliminary report to the interim Legislative Assembly no later than September 15, 2024 and the final report no later than September 15, 2025. As amended, the measure clarifies the newborn bloodspot screening authority shall establish a procedure by rule for waiving fees in certain situations. The measure is declared an emergency and is effective on passage unless otherwise stated. The total fiscal impact for the 2023-25 biennium is \$480,092 General Fund and \$539,664 General Fund for the 2025-27 biennium.

Oregon Health Authority

To support and coordinate the activities of NBSAB, including but not limited to, performing and submitting condition reviews and writing legislative reports, a permanent full-time Program Analyst 3 position is required. The estimated cost of this position over 18 months (.75 FTE) in the 2023-25 biennium includes \$166,977 General Fund for personal services as well as \$18,065 in position-related services and supplies costs.

Based on 2020 data, there were 843 self-pay births and the cost for Newborn Bloodspot screening is \$175 per infant, therefore \$295,050 General Fund is required per biennium for the Newborn Bloodspot Screening fee waiver program.

**In December 2022, the Emergency Board approved OHA to apply for a federal grant from the Health Resources and Services Administration for the purpose of utilizing federal funds to improve the process for adding new conditions to Oregon's newborn screening panel and staff the creation of an implementation guide. In the event that grant is approved, the possibility exists that the federal funds could be utilized, in part, to offset General Fund investment from this legislation, but until OHA learns of an award and the final parameters around the grant, this is not included in the calculations for the fiscal impact statement.**